The metabolic model of heart failure: The role of sodium glucose co-transporter-2 (SGLT-2) inhibition

Muhammad Saad, Umut Gomceli, Pranav Ravi, Andrisael G. Lacoste, Neil Shah, Timothy J. Vittorio

Research output: Contribution to journalReview articlepeer-review

Abstract

Heart failure (HF) is one of the leading causes of hospital readmissions and health care expenditures. With a vast degree of advancements in the clinical approach and diagnosis, its management protocol is limited in terms of enhancing quality of life and prognosis. Type 2 diabetes mellitus (T2DM) is considered as one of the commonly associated comorbid conditions in the HF population. The understanding of the molecular and metabolic models of HF has led to the utilization of therapeutic goals of T2DM in improving HF-related complications. In the recent era, SGLT-2 inhibitors have shown success in decreasing cardiovascular mortality in the T2DM population. This article will help the reviewer to comprehend the pathophysiology of HF and the potential role of SGLT-2 inhibitors in the management algorithm of HF and its associated risk factors in T2DM.

Original languageEnglish
Article number212549
JournalDrugs in Context
Volume7
DOIs
StatePublished - 21 Nov 2018
Externally publishedYes

Keywords

  • Heart failure
  • SGLT-2 inhibitors

Fingerprint

Dive into the research topics of 'The metabolic model of heart failure: The role of sodium glucose co-transporter-2 (SGLT-2) inhibition'. Together they form a unique fingerprint.

Cite this